A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder - Nasser, Azmi; Liranso, Tesfaye; Adewole, Toyin; Fry, Nicholas; Hull, Joseph T; Busse, Gregory D; Chowdhry, Fatima; Cutler, Andrew J; Jones, Nandita Joshi; Findling, Robert L; Schwabe, Stefan (Journal of clinical psychopharmacology, 2021)
Keywords: Adolescent; Adolescent Behavior - drug effects; Adolescent Behavior - psychology; Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - adverse effects; Attention Deficit Disorder with Hyperactivity - diagnosis; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention Deficit Disorder with Hyperactivity - psychology; Behavioral Symptoms - diagnosis; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring - methods; Female; Humans; Male; Psychiatric Status Rating Scales; Symptom Assessment - methods; Treatment Outcome; Viloxazine - administration & dosage; Viloxazine - adverse effects